There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ascentage Pharma Group International Unsponsored ...

JP Morgan sees strong growth for Ascentage Pharma, citing its late-stage cancer drugs. The biotech's 2024 sales surged 342% ...

and SUZHOU, China, March 25, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company engaged in discovering, developing, and commercializing ...

The data to be presented encompasses five of the company’s novel drug candidates: BCR-ABL tyrosine kinase inhibitor olverembatinib (HQP1351), Bcl-2 inhibitor lisaftoclax (APG-2575), FAK/ALK/ROS1 ...

ROCKVILLE, Md. and SUZHOU, China, March 27, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (Ascentage Pharma) (NASDAQ: AAPG; HKEX: 6855) (referred hereinto as “Ascentage Pharma ...

Learn more about Ascentage Pharma Group International's (AAPG) stock grades for Value and Growth and determine whether this Biotechnology stock meets your investment needs.

Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China.

In the current climate of heightened uncertainty and mixed economic signals, Asian markets have shown resilience, with some sectors experiencing growth despite global challenges. In this ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...